These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31472881)

  • 21. Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension.
    Namba M; Kim S; Zhan Y; Nakao T; Iwao H
    Hypertens Res; 2002 May; 25(3):461-6. PubMed ID: 12135327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
    Schmieder RE; Mitrovic V; Hengstenberg C
    Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
    Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.
    Damman K; Navis G; Voors AA; Asselbergs FW; Smilde TD; Cleland JG; van Veldhuisen DJ; Hillege HL
    J Card Fail; 2007 Oct; 13(8):599-608. PubMed ID: 17923350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril.
    van der Ent M; Remme WJ; de Leeuw PW; Bartels GL
    Cardiovasc Drugs Ther; 1998 Sep; 12(4):395-403. PubMed ID: 9825186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nephro-protection: role of arterial pressure in progression of renal pathology. Does a nephro-protective effect depend on the choice of antihypertensive drug?].
    Shestakova MV
    Ter Arkh; 2001; 73(6):64-6. PubMed ID: 11521527
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?
    Schrier RW
    J Am Coll Cardiol; 2006 Jan; 47(1):1-8. PubMed ID: 16386657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Losartan: a review of its use, with special focus on elderly patients.
    Simpson KL; McClellan KJ
    Drugs Aging; 2000 Mar; 16(3):227-50. PubMed ID: 10803861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
    Lassila M; Finckenberg P; Pere AK; Krogerus L; Ahonen J; Vapaatalo H; Nurminen ML
    Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice.
    González-Juanatey JR
    J Hypertens Suppl; 2009 Jun; 27(2):S32-5. PubMed ID: 19491621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
    Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which antihypertensive drugs are the most nephroprotective and why?
    Cravedi P; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2010 Nov; 11(16):2651-63. PubMed ID: 20977400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.